Samsrita Labs Limited submitted a regulatory update regarding the outcome of its Board Meeting held on 04 July 2026, specifically clarifying details under Annexure B regarding changes in shareholding pattern.
The disclosure, made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, references SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and updated on January 30, 2026.
Capital Reduction Details
The Board approved a Scheme of Capital Reduction involving:
- Cancellation and extinguishment of 1,13,74,855 (One Crore Thirteen Lakhs Seventy-Four Thousand Eight Hundred Fifty-Five) fully paid-up equity shares of ₹10 each on a pro-rata basis
- Reduction of issued, subscribed and paid-up share capital from ₹22,74,97,100 (comprising 2,27,49,710 equity shares) to ₹11,37,48,550 (comprising 1,13,74,855 equity shares)
Financial Impact and Purpose
The capital reduction will set off ₹11,37,48,550 against the company's total accumulated losses and share premium balance of ₹11,57,66,110. This will result in:
- Significant reduction of accumulated losses
- Cancellation of entire share premium amount
- Improvement in the company's net worth
- Simplified capital structure
- Enhanced financial ratios and capital efficiency
Shareholding Pattern Impact
Post-reduction, the total paid-up share capital will be 1,13,74,855 equity shares of ₹10 each. The percentage shareholding of each existing shareholder will remain unchanged as before the reduction. No consideration will be paid to shareholders for the cancelled shares.
Promoter Benefits
No benefit will accrue to the promoter/promoter group/group companies from the proposed scheme of capital reduction.
Rationale
The restructuring is intended to realign and reorganize the equity capital structure to better reflect the current capital base, set off past years' accumulated losses, and give a true and fair view of the company's financial position.